Evaluating BioNTech: Insights From 12 Financial Analysts
Evaluating BioNTech: Insights From 12 Financial Analysts
评估biontech:来自12位金融分析师的见解
In the preceding three months, 12 analysts have released ratings for BioNTech (NASDAQ:BNTX), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，12位分析师发布了BioNTech (NASDAQ:BNTX) 的评级，呈现出从看多到看空的广泛观点。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $110.92, along with a high estimate of $122.00 and a low estimate of $98.00. This current average has decreased by 0.61% from the previous average price target of $111.60.
分析师们提供了更深入的见解，建立了12个月的价格目标，显示出平均目标为110.92美元，估价最高为122.00美元，最低为98.00美元。这一当前平均值从之前的平均价格目标111.60美元下降了0.61%。
Breaking Down Analyst Ratings: A Detailed Examination
分析师评级分析：详细分析
A clear picture of BioNTech's perception among financial experts...
通过对最近分析师行动...
登录免费看全文
登录/注册